84. BMC Cancer. 2018 May 4;18(1):526. doi: 10.1186/s12885-018-4331-8.The 21-gene Recurrence Score® assay predicts distant recurrence in lymphnode-positive, hormone receptor-positive, breast cancer patients treated withadjuvant sequential epirubicin- and docetaxel-based or epirubicin-basedchemotherapy (PACS-01 trial).Penault-Llorca F(1), Filleron T(2), Asselain B(3), Baehner FL(4)(5), FumoleauP(6), Lacroix-Triki M(7), Anderson JM(4), Yoshizawa C(4), Cherbavaz DB(4), ShakS(4), Roca L(8), Sagan C(9), Lemonnier J(10), Martin AL(10), Roché H(11).Author information: (1)Department of Biopathology, Centre Jean Perrin and EA 4677 ERTICa, Université d'Auvergne, 58 rue Montalembert, 63000, Clermont-Ferrand, France.frederique.penault-llorca@clermont.unicancer.fr.(2)Department of Biostatistics, Institut Claudius Régaud, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France.(3)Department of Biostatistics, Institut Curie, Paris, France.(4)Genomic Health Inc, Redwood City, CA, USA.(5)University of California, San Francisco, CA, USA.(6)Department of Medical Oncology, Centre Georges François Leclerc, Dijon,France.(7)Department of Pathology, Institut Claudius Régaud, Institut Universitaire duCancer Toulouse-Oncopole, Toulouse, France.(8)Department of Biostatistics, Centre Val d'Aurelle, Montpellier, France.(9)Department of Pathology, Institut de Cancérologie de l'Ouest (site RenéGauducheau), Nantes, Saint-Herblain, France.(10)Unicancer, Paris, France.(11)Department of Medical Oncology, Institut Claudius Régaud, InstitutUniversitaire du Cancer Toulouse-Oncopole, Toulouse, France.BACKGROUND: The 21-gene Recurrence Score (RS) result predicts outcome andchemotherapy benefit in node-negative and node-positive (N+), estrogenreceptor-positive (ER+) patients treated with endocrine therapy. The purpose ofthis study was to evaluate the prognostic impact of RS results in N+, hormonereceptor-positive (HR+) patients treated with adjuvant chemotherapy (6 cycles of FEC100 vs. 3 cycles of FEC100 followed by 3 cycles of docetaxel 100 mg/m2) plusendocrine therapy (ET) in the PACS-01 trial (J Clin Oncol 2006;24:5664-5671).METHODS: The current study included 530 HR+/N+ patients from the PACS-01 parenttrial for whom specimens were available. The primary objective was to evaluatethe relationship between the RS result and distant recurrence (DR).RESULTS: There were 209 (39.4%) patients with low RS (< 18), 159 (30%) withintermediate RS (18-30) and 162 (30.6%) with high RS (≥ 31). The continuous RSresult was associated with DR (hazard ratio = 4.14; 95% confidence interval:2.67-6.43; p <  0.001), adjusting for treatment. In multivariable analysis, theRS result remained a significant predictor of DR (p <  0.001) after adjustmentfor number of positive nodes, tumor size, tumor grade, Ki-67 (immunohistochemicalstatus), and chemotherapy regimen. There was no statistically significantinteraction between RS result and treatment in predicting DR (p = 0.79).CONCLUSIONS: After adjustment for clinical covariates, the 21-gene RS result is asignificant prognostic factor in N+/HR+ patients receiving adjuvantchemoendocrine therapy.TRIAL REGISTRATION: Not applicable.DOI: 10.1186/s12885-018-4331-8 PMCID: PMC5936023PMID: 29728098 